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Parkinson’s disease (PD) and aging lead to gait impairments. Some of the disturbances of gait are focused on step 
length, cadence, and temporal variability of gait cycle. Under experimental conditions gait can be overtly evaluated, 
but patients with PD are prone to expectancy effects; thus it seems relevant to determine if such evaluation truly 
reflects the spontaneous gait pattern in such patients, and also in healthy subjects. Thirty subjects (15 subjects with 
PD and 15 healthy control subjects) were asked to walk using their natural, preferred gait pattern. In half of the trials 
subjects were made aware that they were being evaluated (overt evaluation), while in the rest of the trials the 
evaluation was performed covertly (covert evaluation). During covert evaluation the gait pattern was modified in all 
groups. Gait speed was significantly increased (P = .022); step cadence and average step length were also 
significantly modified, the average step length increased (P = .002) and the cadence was reduced (P ≤ .001). Stride 
cycle time variability was unchanged significantly (P = .084). These changes were not significantly different 
compared between elderly and young healthy controls either. Due to the small sample size, a note of caution is in 
order; however, the significant results suggest that covert evaluation of gait might be considered to complement 
experimental evaluations of gait. 
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Gait impairments are a cardinal sign in Parkinson’s disease (PD) and are present also in aging.1,2 A 
classic kinematic evaluation of gait focuses on gait speed, cadence, and step length; stride time variability 
is also of interest, since it is correlated with the risk of falling.
1-6
 
 
Gait evaluation procedures may themselves influence performance,
7
 and the awareness of being 
evaluated (Hawthorne effect
8,9
) and/or being engaged in a gait task might modify execution, becoming 
unrepresentative of daily living gait. In this respect, Morris et al
10
 evaluated gait covertly in a group of 
patients with PD to control for placebo effects after an intervention based on visual cues. They showed a 
positive treatment effect in overt trials. However, whether it was induced by treatment expectancy or by 
the Hawthorne effect was not clearly discerned. The healthy group did not show differences between 
overt and covert gait evaluation in absence of visual cues; in this case, the effect of treatment expectancy 
was absent. 
 
Hence, it seems relevant to determine the spontaneous execution of gait in the absence of overt 
evaluation in patients with PD, without the influence of any treatment. Although this point is sometimes 
considered by clinicians, it has not been addressed during experimental evaluation. 
 
Here we investigate the putative effect of overt evaluation on parkinsonian spatiotemporal gait 
parameters by comparing participants’ walking patterns when they are aware versus unaware of being 
evaluated (overt and covert evaluation, respectively). Our hypothesis is that overt evaluation causes 
subjects to modify gait patterns from the spontaneous covert gait. 
Methods 
Participants 
We recruited a sample of 30 subjects. Fifteen nondemented patients with idiopathic PD were 
evaluated OFF-dose; ages ranged from 57 to 87 years (mean 68.20; 11 males) and the mean unified 
Parkinson’s disease rating scale (UPDRS) score was 33.20 points (ranging from 13 to 52 points). Fifteen 
healthy subjects were also studied. To account for a putative effect of aging on the outcomes, this sample 
included young (mean 24.87 y, ages ranged from 21 to 37; n = 8, 1 male) and elderly (mean 64.00 y, ages 
ranged from 55 to 71; n = 7, 2 males) subgroups. Procedures were approved by the University of A 
Coruna ethical committee. 
Protocol 
The protocol was bound to the Helsinki declaration, and subjects signed consent forms. Subjects were 
asked to walk normally on level ground for 22 m along a predefined track, having been informed that 
evaluation would be undertaken (overt evaluation) (Figure 1). Only data from the central 17 m were 
analyzed. Once they reached the end of the corridor, they were informed that the trial had ended, asked to 
go back to the start point, and wait for the following trial. However, recording was maintained while 
subjects went back to the starting position, though they were unaware of being evaluated (covert 
evaluation). A total of 13 trials in 8 subjects were discarded because their behavior distorted the normal 
performance of gait (stopping, speaking, and others). A number of 13 trials were added in for these 
subjects to have 5 of each (overt and covert) for analysis. 
  
 
 
 
Figure 1 — Experimental protocol. Subjects were asked to walk along a 22-m corridor. Two photocells (PH) were placed 17 m 
apart, leaving 2.5 m on each side to allow turns, and to obtain steady gait pattern recordings. The figure explains the instructions 
given to the subjects. When the subjects returned to the start point (point B) (covert evaluation) they were not able to see the 
experimenter 
Material 
Gait spatiotemporal parameters were acquired by means of 2 photocells placed 17 m apart at each side 
of the corridor and foot switches to detect contact times (sample at 1 KHz) (Biometrics Ltd., Newport, 
UK). 
Outcome Variables 
Gait speed (m/s) was calculated from the time taken to cover the 17 m. We obtained cadence (steps/s) 
and stride time variability (coefficient of variation [CV], CVstride-time) from contact times. The average step 
length (m) was calculated from gait speed and cadence. CVstride-time was defined as CVstride-time (%) = 
(SD/mean) x 100, and expresses arrhythmicity in stride temporal pattern. Gait outcomes were calculated 
from the mean of the 5 trials. 
Statistical Analysis 
Differences in the groups’ ages were tested with t tests. Each of the 4 kinematic variables was 
analyzed by means of an ANOVA with repeated measures, with 1 within-subjects factor (overt, covert) 
and 1 between-subjects factor group with 3 levels (PD, elderly control, young control). We also computed 
the partial eta square (η2 𝑝) to estimate the magnitude of the effects. Observed values were expressed by 
the mean and 95% confidence intervals (CI). Due to the reduced sample size in the different groups, the 
statistical test might be not sensitive enough to detect interaction of overt-covert effect between group 
factors. Therefore, to check the influence of the sample size on the significance of the interaction effects, 
we conducted a post hoc power analysis to calculate the smallest mean difference needed for which 
power exceeded 95% as follows: we computed the pooled SD of the within-subject covert-overt 
differences from each SD and the sample sizes, found the minimum effect sizes for which the design had 
95% power for the comparisons between groups in the context of a one-way ANOVA, and converted 
them into the smallest mean differences required to detect differences among groups in the covert-overt 
differences with 95% power. For this purpose we used the statistical package G*Power 3.1.9 (University 
of Düsseldorf, Düsseldorf, Germany). Normality of distributions was assessed by Kolmogorov-Smirnov-
Lilliefors and Shapiro-Wilk tests. Significance was set at P ≤.05. 
Results 
There was no statistically significant difference in age between PD subjects and elderly controls (P = 
.225), but young controls were significantly younger than PD subjects (P < .001). The ages of young and 
elderly controls were not compared statistically since age was the basis of their grouping. 
 
Some analyzed variables changed significantly from overt to covert; this was the case for gait speed 
(F1,27 = 5.909; P = .022. η
2 𝑝= .18), step cadence (F1,27 = 17.013; P ≤ .001, η
2 𝑝 = .387), and step length 
(F1,27 = 11.426; P=.002, η
2 𝑝 = .297). For the CVstride-time, the differences between overt and covert 
evaluation were not significant (F1,27 = 3.213; P=.084, η
2 𝑝 = .106). Figure 2 displays these variables 
pooled and split by group, while Figure 3 displays these variables by individual points. 
 
 
 
Figure 2 — Effect of overt and covert evaluation on gait speed (A), step cadence (B), step length (C), and CVstride-time (D). The figure 
shows the effect of covert evaluation on the kinematic variables in the 3 groups (light solid lines for PD subjects, dashed lines for 
elderly controls, and dotted lines for young controls); the thick solid black lines represent the groups’ pooled responses. Bars 
represent upper and lower limits of 95% CIs. 
  
 
 
 
Figure 3 — Individual effect of overt and covert evaluation on gait speed (A), step cadence (B), step length (C), and CVstride-time (D). 
The figure shows the individual PD responses (solid lines), and also individual responses for the elderly (dashed lines) and young 
(dotted lines) healthy subjects. 
Specifically, gait speed decreased when subjects were aware of being evaluated (1.276 m/s, 95% CI = 
1.185,1.367) compared to covert evaluation (1.294 m/s, 95% CI = 1.206,1.381). On the other hand, when 
subjects were aware of evaluation, step cadence was significantly increased (2.051 steps/s, 95% CI = 
1.978, 2.124) compared with covert evaluation (2.019 steps/s, 95% CI = 1.949,2.089). For average step 
length the pattern reversed, as this variable was significantly shorter when subjects knew the evaluation 
was being performed (0.638 m, 95% CI = 0.580, 0.696) compared to covert evaluation (0.657 m, 95% CI 
= 0.601, 0.713). 
 
Remarkably, the aforementioned effects were not significantly differentially expressed in the 3 groups 
included in the study, such that significant interactions (overt-covert x group) were not observed in gait 
speed (F2,27 = 1.315; P = .285; η
2 𝑝 = .089), step cadence (F2,27 = 1.615; P=.218; η
2 𝑝 = .107), step length 
(F2,27 = 1.881; P =.172; η
2 𝑝 = .122), and CVstride-time (F2,27 = 0.610; P=.551; η
2 𝑝 = .043). 
 
Although the interactions of overt-covert x group were not statistically significant, this does not 
necessarily mean that the behavior of each group (how variables changed from overt to covert) has to be 
considered equivalent; the sample of the study seems to not be large enough to rule out the differences 
among groups. For instance, the largest change in gait speed covert-overt differences is present between 
the PD group (0.005, 95% CI = -0.015,0.024) and the young controls (0.031, 95% CI = -0.011,0.073), 
while the smallest difference between the covert-overt difference in one group and the next group for 
which the comparison had 95% power is 0.034. Sample size might influence the significance of the 
interaction effects, such that comparisons between groups could be underpowered in all variables. Table 1 
shows covert-overt differences between groups; the smallest difference needed to have 95% power for all 
variables. 
  
Table 1 Covert-overt differences for each group 
 Groups N Mean 95% CI Minimum Mean Difference 
      
Speed (m/s) PD 15 0.005 (-0.015,0.024)  
 Elderly control 7 0.017 (-0.008,0.042) 0.034 
 Young control 8 0.031 (-0.011,0.073)  
Step length (m) PD 15 0.006 (-0.006,0.018)  
 Elderly control 7 0.022 (-0.007,0.051) 0.026 
 Young control 8 0.030 (-0.004,0.063)  
Step cadence (steps/s) PD 15 -0.015 (-0.030,0.001)  
 Elderly control 7 -0.045 (-0.099,0.008) 0.036 
 Young control 8 -0.036 (-0.070.-0.001)  
CV (%) PD 15 -0.197 (-0.403,0.010)  
 Elderly control 7 -0.026 (-0.380,0.329) 0.462 
 Young control 8 -0.329 (-1.02.3,0.365)  
      
 
Note. CV = coefficient of variation; PD = Parkinson’s disease 
Finally, despite the fact that effects of covert and overt testing were not differently expressed in the 3 
groups, the groups’ behaviors were statistically different for some variables. This was the case for gait 
speed (F2.27 = 880.1; P < .001; η
2 𝑝 = .97). PD subjects (1.058 m/s, 95% CI = 0.939,1.177) were slower (P 
=.022) compared with the healthy elderly controls (1.309 m/s, 95% CI = 1.135,1.483), and even slower (P 
<.001) than young controls (1.488 m/s, 95% CI = 1.325,1.651; elderly and young controls did not differ 
(P =.135) (Figure 2A). 
 
Likewise, step cadence varied significantly among the 3 groups (F2,27 = 4.131; P =.027, η
2 𝑝 = .234), 
but when compared in pairs, a significant difference (P = .009) was only found between PD subjects 
(2.151 steps/s, 95% CI = 2.056,2.246) and young controls (1.931 steps/s, 95% CI= 1.800,2.061), and none 
compared with the elderly (2.023 steps/s, 95% Cl = 1.884,2.163) (Figure 2B). 
 
The same group differentiations were observed for average step length (F2,27 = 10.425; P < .001; η
2 𝑝 
= .436). Step length was shorter (P =.016) in the PD group (0.499 m, 95% CI = 0.423,0.575) than in the 
elderly (0.669 m, 95% CI = 0.558,0.780), and also shorter (P <.001) compared with young controls 
(0.776 m, 95% CI = 0.672,0.880). Elderly and young controls did not differ (P =.160) (Figure 2C). 
 
Finally, the CVstride-time did not differ among groups (F2,27 = 1.560; P= .229; = η
2 𝑝 = .104) (Figure 
2D). 
Discussion 
We have measured a variety of gait parameters in patients with PD and elderly and young control 
individuals while they were aware that measurements were being taken and compared them to measures 
taken covertly. Our data show that some aspects of gait kinematics are significantly influenced by overt 
evaluation inpatients with PD, but also in healthy subjects.
10 
Interestingly, the gait speed decreased subtly 
under overt observation, while the average step length decreased and step cadence increased. In other 
words, participants took smaller, faster steps when they knew they were being observed, without a large 
change in overall speed. T h is suggests an interesting possibility that the subjects somehow optimized 
their speed, but changed strategy. 
 
Regardless of the mean in g o f the directions of such effects, we understand that a broader message 
can be extracted from our results. Awareness of being evaluated modifies the subjects’ gait patterns 
significantly, even in absence of treatment expectancy. This might condition interpretations of 
experimental results focused on gait impairments in different populations.  
Morris et al
10
 had previously evaluated overt and covert gait as part o f a control experiment on the 
therapeutic effect of visual cu e in g in patients with PD. Remarkably, overt and co vert gait pattern s 
were different in patients with PD during treatment, but absent in u n treated healthy controls. Therefore, 
a different expression of covert and overt testing in the different levels of treatment cannot be discern e d 
in the PD group, as a similar behavior under the same conditions in PD and healthy groups was assumed , 
but not evaluated. 
 
Certain regulatory elements of gait may be automatic.
11,12  
Increasing complexity of second tasks while 
walking alters speed, step/stride cadence, and amplitude, both in PD and healthy subjects. It also seems 
the m ore complex the secondary task, the more impacted the variables.
11
 However, CV o f stride time is 
not affected by secondary tasks in healthy subjects, but it is in PD subjects.
11
 CV may be considered to be 
a marker of gait automaticity since it changes during secondary tasks only in PD subjects, and impaired 
execution of automatic movements is a milestone of PD .
13
 On this framework, it seems that the effect 
observed in our study focuses on the less automatic regulatory elements of gait. 
 
On the other hand, both overt and covert evaluations differentiate groups accord in g to the literature.
3-
10
 Notably, in our study, the variability of stride time was not different between patients with PD and 
healthy subjects; this is probably due to the mild severity of signs in the PD group.
14
 
 
Our results suggest that covert evaluation might be useful to complement gait evaluation protocols; 
however, the sample size of our study was small, and for this reason this point must be confirmed in 
studies with larger samples. Additionally, overt and covert testing might be of interest for the study of the 
cognitive basis of locomotion.
15-17
 
 
Our findings may have implications for the evaluation of gait procedures, which might provide a more 
comprehensive evaluation of the outcomes if complementing overt with covert testing. Subjects scored 
significantly different on several gait parameters under these testing conditions; whether the effect comes 
from awareness of being observed, or from being engaged in a task (regardless of being observed or not) 
remains to be elucidated. It seem s relevant to consider that several studies have demonstrated the critical 
role of a placebo on treatment effect,
18-19
 and also that a Hawthorne effect may reflect a situation where 
expectation (to perform well, to be evaluated) is also present. 
 
This study has some limitations. The sample size used in the work is not large, particularly in regard 
to detecting different behavior during overt and covert observations in the different groups; however it 
seems that the observed effects relate to a phenomenon which might be taken into consideration during 
designing gait evaluation protocols. Future experiments with larger samples should try to unravel the 
neurobiological mechanism s implicated. 
 
In conclusion, it could be relevant to include some covert trials during gait testing to complement the 
overt evaluation of so-called “spontaneous” gait. 
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